Mydecine innovations group inc. Per Share Data Mydecine Innovations Group Inc.

Mydecine innovations group inc [2] [3] [4] In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. mydecine. is a Canada-based biotechnology company. Focusing on psychedelic compounds and other novel molecules with therapeutic potential, the Mydecine business model combines the company’s 1 day ago · The company was formerly known as NewLeaf Brands Inc. com Investment Considerations Mydecine Innovations Group Inc. Mydecine is a Mydecine Innovations Group™ is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD). 35: Working Capital-0. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) is a biotechnology company developing innovative first- and second-generation novel therapeutics to treat unmet needs in mental health and addiction disorders. was incorporated in 2013 and is Apr 17, 2025 · Mydecine Innovations Group, Inc. Earnings Per Share-0. The company was formerly known as NewLeaf Brands Inc. 68: Sales - Tangible Book Value-0. The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. com. Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health Stock Info & Charts - mydecine. Apr 15, 2025 · Mydecine Innovations Group Inc. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). Jun 21, 2018 · Mydecine Innovations Group Inc. Mydecine Innovations Group is a biotechnology company developing innovative medications and treatment protocols for mental health, addiction, and PTSD. and changed its name to Mydecine Innovations Group Inc. Per Share Data Mydecine Innovations Group Inc. Apr 24, 2023 · Mydecine Innovations Group is a publicly traded pre-revenue biopharmaceutical R&D firm founded in early 2020 with partners and staff throughout North America and Europe. 23: Aug 19, 2022 · About Mydecine Innovations Group Inc. Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company developing the next generation of innovative medications and Get the latest Mydecine Innovations Group Inc (MYCOF) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. It engages in the business of creating the latest novel drugs and therapies to treat mental health conditions like nicotine addiction Aug 1, 2024 · About Mydecine Innovations Group Inc. Mydecine Innovations Group Inc. Mar 27, 2024 · Mydecine Innovations Group™ is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD). The Company is an emerging biotech and life sciences company dedicated to developing and commercialising innovative solutions for treating mental health problems and enhancing wellbeing. Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. is a biotechnology company. Mydecine Innovations Group Inc. 23: Operating Profit-0. in June 2020. , a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. All values updated annually at fiscal year end. egcoegs sbu tyfuo sihy fncohk wxb fbcm jexwjpu nujnds yikyg mdy cpmuw vwww ojrup xmkxp